U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07948200) titled 'Urinary DNA Methylation Testing (Bladder EpiCheck(R)) and Its Peri-operative Kinetics for the Prediction of Residual Disease at Second Transurethral Resection in T1 Non-muscle-invasive Bladder Cancer' on Nov. 13.

Brief Summary: European Association of Urology (EAU) guidelines mandate a second transurethral resection of bladder tumour (re-TURBt) for patients with high-grade or pT1 non-muscle-invasive bladder cancer (NMIBC) to eradicate residual disease and avoid understaging. However, 30% to 50% or more of patients undergoing re-TURBt have no residual tumour found upon re-resection, incurring surgical and anaesthetic risks, potential...